Valuation: Genix Pharmaceuticals Corporation

Market Cap 1.22M 859K 763K 712K 649K 82.57M 1.24M 8.62M 3.34M 42.21M 3.22M 3.15M 135M P/E 2024
-40.5x
P/E 2025 -5.33x
Enterprise Value 2.22M 1.56M 1.39M 1.29M 1.18M 150M 2.24M 15.66M 6.07M 76.66M 5.86M 5.73M 246M EV / Sales 2024
929,496,174x
EV / Sales 2025 -
Free-Float
53.08%
Yield 2024 *
-
Yield 2025 -
3 months+33.33%
Current year-20.00%
Current year 0.02
Extreme 0.015
0.02
1 year 0.02
Extreme 0.015
0.04
3 years 0.02
Extreme 0.015
0.09
5 years 0.02
Extreme 0.015
0.19
10 years 0.01
Extreme 0.01
0.3
Manager TitleAgeSince
Chief Executive Officer 57 02/08/2018
Director of Finance/CFO - 03/05/2026
President - 20/05/2021
Director TitleAgeSince
Director/Board Member 57 02/08/2018
Director/Board Member 76 10/03/2019
Director/Board Member 48 04/09/2019
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/25 Option

Chairman

1,000,000 1.6885%
09/09/25 Option

Chairman

1,000,000 1.6885%
09/09/25 Option

Chief Executive Officer

1,000,000 1.6885%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-33.33%-50.00% 859K
+1.16%-3.43%+36.07%+115.04% 1,019B
-0.77%-5.60%+35.72%+64.63% 617B
-0.84%-0.58%+12.36%+77.95% 464B
-2.33%-3.01%+61.79%+41.24% 356B
+0.52%-2.08%+20.67%+41.06% 333B
+0.10%-3.36%+10.89%+34.50% 267B
-0.59%-4.92%-6.66%+8.95% 244B
-0.68%-2.79%+35.30%+51.84% 218B
-0.56%-4.10%+28.44%+93.66% 179B
Average -0.36%-3.19%+20.12%+47.89% 369.72B
Weighted average by Cap. -0.14%-3.54%+29.08%+70.63%

Financials

2024 2025
Net sales 0 0 0 0 0 0.27 0 0.03 0.01 0.14 0.01 0.01 0.45 -
Net income -73.2K -51.35K -45.62K -42.58K -38.81K -4.94M -73.88K -515K -200K -2.52M -193K -189K -8.1M -335K -235K -209K -195K -178K -22.59M -338K -2.36M -914K -11.55M -882K -863K -37.07M
Net Debt 804K 564K 501K 468K 426K 54.23M 812K 5.66M 2.19M 27.72M 2.12M 2.07M 88.98M 999K 701K 623K 581K 530K 67.39M 1.01M 7.03M 2.73M 34.45M 2.63M 2.57M 111M
Logo Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation is a Canadian ophthalmic drugs company. The Company is a formulator, manufacturer, licensor and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its operations consist primarily of the research, development, manufacture, in-licensing and sales of novel and healthcare products, focusing on proprietary over the counter (OTC) nutraceuticals and generic pharmaceuticals. The Company has been marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Timolol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Moxifloxacin Hydrochloride 0.5% Eye Drops, Prednisolone Acetate 1% Eye Drops, Olopatadine 0.1% Eye Drops, and others.
Employees
4,000
  1. Stock Market
  2. Stocks
  3. GENX Stock